As a matter of fact and as a confirmation of the utility of integrated conventional cytogenetics and mutational screening, the introduction of NPM1 mutation and FLT3 allelic ratio in the new AML guidelines ELN 2017 helped to better stratify some of the previously considered “intermediate risk” patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.